Upload
nigel-jordan
View
222
Download
0
Embed Size (px)
Citation preview
By: NICOLE STEVENS
ObjectivesDefinition of apnoeaIdentify causes and incidence of apnoeaIdentify the categories of apnoeaDiscuss the pathophysiology of apnoeaDiscuss apnoea of prematurityIdentify risk factors for apnoeaDiscuss nursing management of apnoeaPharmacological management of apnoea
IntroductionApnoea is a disorder of respiratory controlIt more commonly effects preterm infantsIs rare among full term healthy infants and, if
present usually indicates an underlying pathology
Several mechanisms have been proposed to explain apnoea, and many clinical conditions have been associated with its development
Apnoea of prematurity (AOP) is seen in infants < 37 wks gestation, with the incidence increasing as gestational age decreases
DefinitionThe cessation of respiratory inflow; it is a
disorder of respiratory control common in premature infants
Pathologic apnoea is defined as a respiratory pause of greater than 20 seconds or any pause in respirations associated with cyanosis, marked pallor, marked hypotonia, or bradycardia (Theobald et al).
Apnoea of prematurity (AOP) is a pathological apnoea with no definable cause in infants < 37 wks gestation, usually presenting between days 3 – 7 of life
Causes of ApnoeaDay 1 – 2SepsisHypoglycaemiaImpending respiratory failurePolycythaemiaDays 3 – 6SepsisImpending respiratory failurePDAMassive IVHAOP
Causes of ApnoeaLate OnsetSepsisProgressive post-extubation atelectasisOut grown dose of methylxanthine (eg.
caffeine)Presenting symptom of RSV infection
IncidenceApnoea occurs inMost infants < 30 wksAbout 50% of infants at 30 – 32 wksAbout 10% of infants at 34 wks
Usually resolves by 36 wks CA
Good evidence that it is not a risk factor for SIDSNo evidence that AOP causes subsequent neurodevelopmental
morbidity, although recurrent apnoea is concerning because of the effects of the repeated episodes of tissue hypoxia (especially on the gut and the brain)
Categories of ApnoeaApnoea has three major types: central, obstructive &
mixedCENTRAL APNOEANo respiratory effort, displayed by a lack of chest wall
movement, and no breath sounds heard on auscultation
The central controlling area for breathing, called the respiratory centre, is in the lower part of the brain stem, in the medulla oblongata
The automatic breathing rhythm is controlled by inspiratory and expiratory neurons; this automatic rhythm can be altered by afferent information
Categories of ApnoeaCentral cont...An information exchange occurs to (afferent) and
from (efferent) the respiratory centre of the brainAn afferent supply of information travels to the
respiratory centre of the brain from central chemoreceptors, peripheral chemoreceptors, other areas of the brain and from the lungs
Chemoreceptors are cells that respond to chemical stimuli; central chemoreceptors are located in a part of the brain stem and they respond to the acidity of the CSF and the output from these cells influences breathing
Categories of ApnoeaThe peripheral chemoreceptors that feedback
to the respiratory centre are the carotid and aortic bodies – which are small pieces of tissue containing chemoreceptors that respond to O2 & CO2 levels in arterial blood
The carotid body in particular provides continual feedback; if the PaO2 goes below 80mmHg or the PaCO2 goes above 40mmHg then there will be an immediate increase in breathing rate
Categories of ApnoeaOther parts of the brain can also provide
feedback to the respiratory centre and cause an alteration in respiratory rate eg: conscious or deliberate hyperventilation, hyperventilation in response to intensely emotional or distressing situations or sights, and hyperventilation in response to massive blood loss (coordinated by the autonomic system in the brainstem and the vasomotor centre in the brain stem)
The lungs: provide feedback via stretch receptors in the elastic tissues of the lung, the chest wall and the pulmonary blood vessels; the bronchi also have receptors cells
Categories of ApnoeaOnce messages are received by the respiratory
centre it will send messages back out to the body via the efferent nerves
They pass down the spinal cord to the diaphragm, intercostal muscles & accessory muscles of inspiration in the neck
The diaphragm is supplied by the phrenic nerve (C3-5)
The intercostal muscles by the segmental intercostal nerves (T1-12)
The accessory muscles by the cervical plexus (C1-4)
Categories of ApnoeaSo, in summary, central apnoea occurs when there
is a lack of respiratory effort due to a failure in the feedback messages getting to the respiratory centre or a failure of the respiratory centre to send the messages out to the peripheral nerves and respiratory muscles required for oxygenation and ventilation
This can be due to immaturity in the system as seen in premature infants who have a decreased response to hypercapnia; head trauma; and toxin-mediated apnoea (analgesics, anaesthetics, infections)
Categories of ApnoeaOpioid drugs, such as morphine, pethidine &
fentanyl (as well as illicit substances such as heroin), depress the respiratory centre’s response to hypercarbia
Some anaesthetic agents may also do this (such as with women that require a GA for caesarean section)
These drugs can cross the placenta to the fetus and when born the infant can have have profound apnoea and require prolonged assistance with IPPV until spontaneous respirations are established
Categories of ApnoeaOBSTRUCTIVE APNOEAResults from attempts to breath through an
occluded airwayCan be the result of a congenital problem
(smaller airway patency)Other causes of obstructive apnoea are an
aspirated foreign body or vocal cord paralysis
Categories of ApnoeaMIXED APNOEAHas characterisics of both mixed and
obstructiveEg: a premature infant with central apnoea
who has an obstruction due to nasal congestion brought on by a viral illness
Gastro oesophogeal reflux is thought to cause this mixed picture as regurgitated gastric contents may occlude the airway and block laryngeal chemoreceptors from sending signals for dilation to the brain
Primary & Secondary ApnoeaTypes of apnoea at delivery:Primary: when asphyxiated the infant responds
with an initial increase in respiratory effort, they then become apnoeic and heart rate drops – but they will be quickly responsive to tactile stimulation +/- IPPV
Secondary: when asphyxia continues beyond primary apnoea, the infant responds with gasping respirations, falling HR and BP; they take a last breath, enter the secondary apnoea phase and death will occur if resuscitation does not commence immediately. Will not be responsive to stimulation
Apnoea of PrematurityAOP is a diagnosis of exclusion and should only be
considered after secondary causes have been excluded
Premature babies are more at risk or apnoea because of :
Central immaturityAlterations in CO2 responseHypoxiaImmature sleep patternsGreater risk of pharyngeal obstructionGreater risk of laryngeal obstructionMore reflux induced problems
Upper Airway Anatomy
Sleep StatesPremature babies are at increased risk of
apnoea because of immature sleep patternsBreathing in infants is strongly influenced by
sleep statesApnoeic spells occur more frequently in REM
sleep than active sleepREM sleep predominates in preterm infants
(80% of the day)
Differential DiagnosisAlthough AOP is the most common cause of
apnoea there are other conditions that may cause or aggravate apnoea:
Anatomical anomalies of upper airwayInfection: sepsis, NECTemperature disturbancesMetabolic: hyper or hypocalcaemia,
hypoglycaemia, hyponatraemia, acid/base disturbances
Haematological: anaemia, polycythaemiaPulmonary: impending respiratory failure
Differential DiagnosisCVS disorders: causes of cardiac failure or
impaired oxygenation eg. PDA, congenital defects, arrhythmias
CNS disorders: IVH, intracranial haemorrhage, seizures, asphyxia, increased intracranial pressure, cerebral abnormalities
Drugs: prenatal (narcotics, betablockers, MgSO4, maternal smoking) and postnatal (sedatives, hypnotics, narcotics, prostaglandin)
MonitoringAll infants < 34 wks gestation should be monitored
for apnoeaMonitoring can be with a full cardiorespiratory
monitor, SaO2 and heart rate monitor or an apnoea monitor only
Type of monitoring required will depend on other factors: gestation of the baby, availability of equipment & what level of care can be provided at the particular hospital
If the preterm baby can not be adequately monitored & managed they need to be moved to a hospital that can provide an appropriate level of care
Evaluation of ApnoeaTake a history, including apgar scores Physical examinationSepsis risk?Consider age (GA, and day of life)See if apnoeic events are associated with feedsDetermine frequency of events and intervention
required (if any) Evaluated associated bradycardia and cyanosisRepeated apnoeas with quick recovery, or any
profound apnoeas need to be reported to medical personnel
InvestigationsSeptic workup (FBE, CRP, blood culture +/-
SPA of urine & LP)Other pathology: Electrolytes, TBG, gasesChest XrayAbdominal XrayNeurological investigations (CrUS, MRI,
physical assessment)Reflux investigations
Emergency ManagementProvide tactile stimulation Reposition, paying attention to minimising
airway obstruction, ie. Get chin off chest – position head in a neutral or slightly extended position
Suction airway briefly, repeat tactile stimulation
Provide IPPV in air/oxygen – CALL FOR HELPIf still no response, continue IPPV and
consider intubation
Symptomatic ManagementIf an infectious aetiology is suspected treat with
antibioticsCorrect any electrolyte disturbancesSupportive management for respiratory compromiseConsider managment of cardiovascular issues eg.
indocid for PDA, inotropes for low BP or poor cardiac contractility
If CNS issues: antiseizure medication, antimicrobials (menigitis), ventricular decompression
Consider PRBC and ongoing iron supplementationGI considerations: NEC, obstruction, dysmotility
Ongoing ManagementNot all episodes of apnoea require treatment;
the following is suggested list from the NETS handbook:
Episodes needing brief stimulation for cyanosis & bradycardia: > 6 events every 12 hrs
Episodes needing vigorous stimulation & oxygen: > 1 event every 24 hrs
Episodes needing IPPV +/- oxygen: > 1 event every 24 hrs
Ongoing ManagementPosition infant to avoid upper airway
obstruction (neck rolls, prone or side lying)Give smaller volume feeds (increase frequency
with smaller volumes and/or reduce TFI if possible), to avoid excessive stomach distention
Consider maintaining temperature at lower end of normal spectrum
Low amounts of ambient oxygen (ie cot oxygen at 23-24%) – must have continuous SaO2 monitoring, and upper limit lowered to prompt weaning to avoid hyperoxia
Pharmacological ManagementMethylxanthines and continuous positive airway
pressure (CPAP) form the mainstay of treatment of apnoea in neonates; mechanical ventilation is reserved for when the apnoea is resistent to these treatments
Methylxanthines include caffeine and theophylline(oral form) & aminophylline(IV form); are thought to stimulate breathing efforts in neonates and have been used in clinical practice since the 1970’s
Cochrane review (2010) suggests caffeine preferable to theophylline
Pharmacological ManagementCAFFEINEHas a comparable efficacy to theophylline but
with less side effects, and does not require regular blood sampling for levels
Caffeine has a longer half life (so only requires once daily administration), more reliable enteral absorption and there are less instances of having to reduce doses due to tachycardia and feed intolerance
Different institutions will vary in practice guidelines for prophylactic administration and maintenance doses
Pharmacological ManagementCaffeine cont..Loading dose 20mg/kg (IV or oral)Then maintenance dose of 5mg/kg daily(may
see increases in this dose in symptomatic infant to 10mg/kg)
Dose may be ceased in the asymptomatic infant from 34-36wks CA, or in some cases, the infant may be allowed to ‘grow out of the dose’ – not increasing the dose as the infants weight increases
Pharmacological ManagementCaffeine cont...Other infants may remain symptomatic and
continue on caffeine beyond term corrected ageInfants born at < 28wks GA will often remain
symptomatic of AOP beyond term corrected ageBecause of caffeines long half life (approx.
100hrs) infants should be monitored for 5 – 7 days post cessation of medication (apnoea monitors are usually sufficient if the infant is otherwise well)
Other ManagementCPAPUsed to manage obstructive and mixed apnoeasSplints the nasopharynx and prevents
pharyngeal collapesStabilizes the chest wall musculatureAlters various reflexesIncreases functional residual capacityInitial settings would be 5 – 7 cm/H2O, adjusted
according to clinical responseNETS should be consulted if in a non-NICU
centre
ParentsInform and educate parents of risk of apnoea
(particularly if they have had a premature baby)
Inform if apnoeas are occurring and if treatment is required
Explain expected length of treatmentExplain need for ongoing monitoring
(including after medications are ceased)Provide reassuranceConsider CPR training for any parents who
have had a baby in a SCN or a NICU
Reference List Aggarwal,R.,Singhal,A.,Deorar,A.,& Paul,V. Apnea in the Newborn.
Division of Neonatolgy. Department of Paediatrics. All India Institute of Medical Sciences. www.newbornwhocc.org
Hansen, T.N., Cooper, T.R. and Weisman, L.E. (1995) Neonatal Respiratory Diseases handbooks in Health Care Co., Newtown, Pennsylvania
Theobald,K.,Botwinski,C.,Albanna,S.& McWilliam,P. (2000). Apnea of Prematurity: Diagnosis, Implications for Care and Pharmacologic Management. Neonatal Network, Vol 19. No. 6 17 – 22.
Neonatal Handbook: Apnoea. (2011). www.rch.org.au/nets/handbook